A16Z · 18 November 2026

Investing in Boltz

A16Z

A16Z outlines its rationale for leading Boltz's $110M Series A, a molecular design AI platform that offers frontier models on a consumption-based basis to pharma and biotech companies, with 50x growth in token usage in four months.

Read the full post on A16Z ↗

Topics: Biotech & Life Sciences · AI Infrastructure

Published by A16Z · their site ↗

More from A16Z

SandHill indexes 800+ venture capital blogs and newsletters and sends the best of them every Sunday. Browse the sources · browse by topic · read the blog.